These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26322366)

  • 21. Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001 - 2009).
    Xiang YT; Kreyenbuhl J; Dickerson FB; Ungvari GS; Wang CY; Si TM; Lee EH; Chiu HF; Lai KY; He YL; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong MK; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):500-4. PubMed ID: 22541750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database.
    Kose E; Uno K; Hayashi H
    Yakugaku Zasshi; 2017; 137(1):111-120. PubMed ID: 28049887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility.
    Kasten M; Brüggemann N; König IR; Doerry K; Steinlechner S; Wenzel L; Lohmann K; Klein C; Lencer R
    Psychopharmacology (Berl); 2011 Apr; 214(3):729-36. PubMed ID: 21072501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients.
    Høiberg MP; Nielsen B
    Nord J Psychiatry; 2006; 60(3):207-12. PubMed ID: 16720511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic-induced extrapyramidal symptoms and their management.
    Dayalu P; Chou KL
    Expert Opin Pharmacother; 2008 Jun; 9(9):1451-62. PubMed ID: 18518777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial.
    Gassó P; Mas S; Papagianni K; Ferrando E; de Bobadilla RF; Arnaiz JA; Bioque M; Bernardo M; Lafuente A
    Pharmacogenomics; 2014 Jan; 15(1):17-28. PubMed ID: 24329187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel antipsychotics and extrapyramidal side effects. Theory and reality.
    Horácek J
    Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():34-42. PubMed ID: 11072763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
    Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
    Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of antipsychotics: Clinical utility and implementation.
    Arranz MJ; Salazar J; Hernández MH
    Behav Brain Res; 2021 Mar; 401():113058. PubMed ID: 33316324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
    Gentile S
    J Clin Psychopharmacol; 2007 Feb; 27(1):35-45. PubMed ID: 17224710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms.
    Murphy JE; Stewart RB
    Am J Hosp Pharm; 1979 May; 36(5):641-4. PubMed ID: 36755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Extrapyramidal effects of antipsychotic drugs].
    Kulisevsky J; Otermin P
    Neurologia; 2003 Jun; 18(5):262-8. PubMed ID: 12768512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
    Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
    Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The future (or lack of future) of personalized prescription in psychiatry.
    de Leon J
    Pharmacol Res; 2009 Feb; 59(2):81-9. PubMed ID: 18996200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Shakuyaku-Kanzo-to on Extrapyramidal Symptoms During Antipsychotic Treatment: A Randomized, Open-Label Study.
    Ota T; Miura I; Kanno-Nozaki K; Hoshino H; Horikoshi S; Fujimori H; Kanno T; Mashiko H; Yabe H
    J Clin Psychopharmacol; 2015 Jun; 35(3):304-7. PubMed ID: 25839338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Extrapyramidal side-effects: avoidance, diagnosis and treatment].
    Fleischhacker WW; Widschwendter C
    Psychiatr Prax; 2005 Apr; 32 Suppl 1():S25-30. PubMed ID: 15818517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective prescribing of atypical antipsychotics.
    Breekveldt-Postma NS; Schillevoort I; Nolen WA; Veraart CP; Herings RM
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):25-30. PubMed ID: 15508132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.